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During recent years, the treatment of chronic hepatitis C has increased in efﬁcacy.
Initially, the only approved treatment for this disease was interferon-alpha (IFN-a)
monotherapy, achieving a 15% rate of sustained response. Subsequently, a combination
of IFN-a plus ribavirin showed a greater efﬁcacy: up to 40% success with 3MU of IFN-a
three times weekly and 1000–1200mg of ribavirin daily in naive patients and in those
who had relapsed after a course of IFN-a therapy. Pegylated interferon (PEG-IFN), due to
its better efﬁcacy and tolerance, has displaced the use of recombinant IFN. Nevertheless,
the sustained response rate mainly depends on HCV RNA load and HCV genotype.
Presumably, in future, new strategies based on gene therapy will play an important role
in the treatment of chronic hepatitis C.
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TREATMENT OF CHRONIC
HEPATITIS C WITH INTERFERON
Interferon monotherapy
The ﬁrst approved treatment for chronic hepatitis
C was recombinant interferon-alpha (IFN-a). This
antiviral drug is administered at doses of 3MU,
three times weekly, for 12months. With this regi-
men, some 15–20% of the treated patients show a
sustained response (normal ALT values and
serum HCV RNA negative at the end of the
post-treatment follow-up period) [1]. IFN-b and
IFN-g have also been evaluated as treatment for
chronic hepatitis C. Up to now, the treatment
schedules assessed with these interferons have
not improved on the results obtained with IFN-a
monotherapy [2,3].
IFN-aþ ribavirin
The combination of IFN-a and ribavirin leads to a
2–3-fold increase in the possibility of achieving a
sustained response in comparison with IFN-a
monotherapy. In this combination, IFN-a is admi-
nistered at doses of 3MU, three times weekly,
subcutaneously, in addition to 1000–1200mg daily
of ribavirin according to body weight (1200mg in
those patients whose weight is >75 kg; 1000mg
if the weight is 75 kg or lower). The rate of
sustained response 6 months post-treatment is
30–40% in patients receiving combination therapy
[4–6]. Both the HCV RNA concentration in serum
and virus genotype have a major impact on
response rates to combination therapy; a better
response is observed in patients with a low viral
load and HVC genotype 2 or 3. There is no consen-
sus on how long combination treatment should be
used in relation to HCV RNA levels [5–7]. It must
be maintained for at least 24weeks, and then a
decision to continue or stop therapymust bemade,
depending on serum HCV RNA and genotype
(Table 1).
In patients who relapse after IFN-a, retreatment
with IFN-a and ribavirin has a better chance of
providing a sustained response than does retreat-
ment with IFN-a alone [8]. In this kind of patient,
the schedule may also vary according to viral load
and HCV genotype. Thus, patients with genotype
1b whose viral load is >800 000 IU/mL must
receive treatment for at least 12months, unless
HCVRNA continues to test positive after 6months
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of therapy, in which case treatment must be
stopped. For genotype 1b patients whose viral
load is <800 000 IU/mL, a 6-month treatment
course is sufﬁcient. In patients with genotypes
other than 1b, treatment for 6months is appropri-
ate, independent of the viral load.
In summary, as it has been demonstrated that a
combination of IFN-a and ribavirin achieves
higher sustained response rates in both naive
and relapsed patients [9,10], IFN-a monotherapy
must be administered only in those cases where a
clear contraindication exists for ribavirin [9].
Pegylated IFN-a
Recently, a modiﬁcation consisting of the addition
of a polyethyleneglycol (PEG) moiety has been
introduced into the IFN-a molecule; this changes
its properties and improves IFN-a efﬁcacy. Once
injected, PEG-IFN remains in the blood at a con-
stant level for approximately 168 h. The drug’s
antiviral activity is retained for at least 7 days,
and thus a single dose administered once weekly
may be sufﬁcient.
There are two types of PEG-IFN available: PEG-
IFN-a2b and PEG-IFN-a2a. Several studies have
assessed the tolerance, safety and efﬁcacy of both
PEG-IFNs in comparison with conventional re-
combinant IFN-a. PEG-IFN-a2b leads to a sus-
tained response rate of 20–25%, compared with
12–17% achieved with recombinant IFN-a2b. The
best schedule consists of 1.5 mg/kg body weight of
PEG-IFN-a2b, once weekly for 6–12months; this
dosage is well tolerated. The efﬁcacy of PEG-IFN-
a2a is at least twice that of recombinant IFN-a2a
[11,12]. The best results have been obtained with a
dose of 180 mg of PEG-IFN-a2a once weekly for
48weeks: 39% of sustained response versus 19%
with recombinant IFN-a2a.
PEG-IFN has also been evaluated in combina-
tion with ribavirin. At present, the recommended
dosage for combination therapy with PEG-IFN-
a2b is 1.5 mg/kg body weight once weekly plus
800–1200mg ribavirin [13,14]. The duration of
treatment can be established following the same
criteria as for combination therapy using IFN-a. In
a similar way, the combination of PEG-IFN-a2a
and ribavirin has proved to be superior to IFN-a2a
monotherapy [14].
From the data collected in several trials, it can be
concluded that PEG-IFN-a is equally well toler-
ated, but is more convenient to administer and
more efﬁcacious, than conventional recombinant
IFN-a.
RETREATMENT OF PATIENTS WHO
HAVE FAILED TO RESPOND TO A
PREVIOUS CYCLE
There is no consensus concerning the therapeutic
strategy to be used in those patients who have
failed to respond to a previous cycle of IFN-a
monotherapy or combination treatment with
IFN-a plus ribavirin, and several approaches have
been assessed. Results of the retreatment of non-
responding patients with high doses of IFN-a,
with IFN-aþ ribavirin, with IFN-aþ amantadine,
with vitamin Eþ IFN-a, or phlebotomies prior to
administration of IFN-a monotherapy, have been
disappointing [15–19].
The most promising results have been obtained
using ribavirin in combination with amantadine
and IFN-a. The ﬁrst study using this triple therapy
in chronic hepatitis C sufferers who had failed to
respond to a previous treatment was performed by
Brillanti et al. [20]. In this trial, the percentage of
patients showing a sustained biochemical response
was 57% among those treated with the triple
Table 1 Recommended treatment period for interferonþ ribavirin therapy according to serum HCV RNA load and HCV
genotype
HCV RNA Status at week 24
Positive Negative
HCV Genotypes 1, 4 and 5
Basal HCV RNA> 800 000 IU/mL Stop therapy Continue therapy for 48weeks
Basal HCV RNA< 800 000 IU/mL Stop therapy Stop therapy
HCV Genotypes 2 and 3
Independent of basal HCV RNA Stop therapy Stop therapy
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combination and 10% in the group of patients
treated with IFN-a plus ribavirin. Furthermore,
48% of the patients who received the triple therapy
had a sustained virologic response, while this only
occurred in 5% of those treated with IFN-a plus
ribavirin.
The results of this study are encouraging,
although it should be noted that the doses of
IFN-a used were higher (5MU) than the standard
dose (3MU), while ribavirin doses were slightly
lower (800–1000mg). In any case, it is necessary to
carry out more studies including a higher number
of patients, to conﬁrm these results.
OTHER TREATMENT APPROACHES
In an attempt to improve the sustained response
rates, several other drugs have been assessed for
treating patients with chronic HCV infection.
Ribavirin monotherapy may be useful in some
cases, as the administration of this agent alone at
doses of 1000–1200mg for 6–12months may
induce a decrease in ALT levels in 30–50% of
patients, although serum HCV RNA load does
not change [21–23]. Furthermore, when ALT levels
become normal, there is also an improvement in
the liver histology, mainly at the expense of the
necroinﬂammatory inﬁltrate. However, reactiva-
tion of the liver disease occurs when therapy is
discontinued. This could indicate that ribavirin
should be given intermittently (depending on
transaminase levels) or indeﬁnitely, although this
may induce signiﬁcant side-effects.
Japanese studies have demonstrated that gly-
cyrrhizin induces a signiﬁcant decrease in ALT
levels in comparison with a control group, and an
improvement in the histologic damage in 71% of
treated patients [24,25]. However, as it must be
intravenously administered and the response is
not sustained, this strategy has no clinical signiﬁ-
cance.
Amantadine was applied for the treatment of
chronic hepatitis C for the ﬁrst time in 1997, and
the sustained response rate reported was 18% [26];
however later studies have not conﬁrmed this
ﬁnding [27,28].
In several studies it has been demonstrated
that the combination of ursodeoxycholic acid and
IFN-a induces an earlier and prolonged ALT nor-
malization than the IFN-a alone [29,30]. In our
experience, among patients who have failed to
respond to a previous IFN-a cycle, 38% of the
patients with basal gammaglutamil transpepti-
dase (GGTP) values above basal ALT values
showed normalization of the levels of both
enzymes with this combination, while this only
occurred in 4% of the cases with basal ALT levels
above GGTP ones. These results indicate that a
combination of ursodeoxycholic acid and IFN-a
may be of beneﬁt in some non-responding patients.
VX-497, a nucleoside analog, has been used in
non-responding patients, achieving 20–25% of
ALT normalization, but showing no antiviral
activity [31].
Maxamine (histamine dihydrochloride) is cur-
rently under evaluation in a phase II trial, in
combination with IFN-a [32]. Preliminary results
are promising, as 61% of the treated patients have
shown a complete response. Nevertheless, the
long-term efﬁcacy of this combination remains
to be demonstrated.
Non-steroidal anti-inﬂammatory drugs, such as
indomethacin, tenoxican and ketoprofen, in com-
bination with IFN-a, have also been used for the
treatment of chronic hepatitis C [33–35]. Only the
combination of ketoprofen plus IFN-a induced a
higher sustained response rate than IFN-a mono-
therapy, but larger studies are needed to conﬁrm
this result.
Cytokines such as interleukin-2 (IL-2), IL-10 and
IL-12 have been administered to naive as well as to
non-responding patients [36–38]. Of these, only IL-
10 has shown a beneﬁcial effect on ALT levels and
has effected an important decrease of the liver
inﬂammation; but it had no antiviral activity.
Thymosin-a1, alone or in combination with
IFN-a, has shown better results than those ob-
tained with IFN-a alone [39,40], but more studies,
including non-responding patients, are needed to
conﬁrm the potential therapeutic effects of this
peptide.
Other drugs that have been used in patients
with chronic hepatitis C, alone or in combination
with IFN-a, are: histamine, rimantidine, pentoxi-
fylline, isoprinosine, colchicine, G-CSF, GM-CSF,
cimetidine and N-acetylcysteine [41–49]. None of
them, at least with the schedules that have been
assessed, have provided better results than IFN-a
monotherapy.
Currently, other approaches are under evalua-
tion in ‘in vitro’ studies. Among them, the most
promising results are being obtained with new
nucleoside analogs, such as levovirin [50], with
therapeutic DNA vaccines [51], and with gene
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therapy based on the use of ribozymes, DNA-
zymes, and antisense molecules [52–54].
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